Poraibi 销售预测与市场规模分析（2034 年）

推动 Poraibi 成长的关键因素

1. 扩大市场占有率并增加新患者数量

• Poraivy（ Polatuzumab vedotin ）是罗氏公司开发的抗体药物复合体（ADC），它正在改变瀰漫性大B细胞淋巴瘤（DLBCL）市场的格局，尤其是在一线和復发/难治性患者中。
• 在关键临床试验中表现出的显着生存获益的支持下，随着 Poraivy 被纳入标准治疗方法，新患者的数量正在增加。
• 罗氏针对血液学和肿瘤学领域的针对性商业策略，加上加强对医生的教育和纳入指南，正在加速学术医院和社区癌症中心对相关技术的应用。

2. 主要适应症的扩展

• DLBCL 一线治疗：对于先前未接受治疗的 DLBCL 患者，Porivy 和 R-CHOP 的联合治疗已成为 R-CHOP 的主要替代方案，并得到了优异的无恶化存活期结果的支持。
• 復发/难治性瀰漫性大B细胞淋巴瘤：继续使用苯达莫司汀和Rituximab（Pola-BR）联合治疗，支持其在后续治疗中继续使用。
• 更广泛的 B 细胞淋巴瘤：正在进行的研究正在评估 Poraivy 在其他侵袭性和非侵袭性 B 细胞非何杰金氏淋巴瘤中的疗效。
• 研发管线和联合疗法：与新型药物和免疫疗法的联合应用可能会进一步扩大 Poraivy 在各个治疗领域的作用。

3. 地理扩张

• 全球商业发展：Poraibee 已核准在美国、欧洲和日本等主要市场上市。
• 新兴市场：罗氏成熟的肿瘤治疗平台和不断扩大的先进淋巴瘤治疗方案支持其向新兴市场扩张。
• 亚太地区成长：淋巴瘤发生率上升、诊断率提高以及生物製药的普及可望推动亚太地区加速成长。

4. 新适应症的核准

• 核准用于第一线 DLBCL：Poraivy 与 R-CHP联合治疗用于治疗以前未接受过治疗的 DLBCL 的核准，大大扩展了治疗选择。
• 扩大适应症的优势：在初始治疗和復发/难治性治疗领域核准，增强了罗氏的竞争优势，并使其收入来源多元化。
• 监管进展：正在进行的研究有望完善和扩大特定 DLBCL 亚组的适应症。

5. 对瀰漫性大B细胞淋巴瘤治疗的需求势头强劲

• 侵袭性淋巴瘤方面存在巨大的未满足需求：儘管旨在根治性，但相当一部分 DLBCL 患者会復发或对一线治疗无反应，导致对改进的治疗方法的持续需求。
• 令人信服的临床结果：无恶化生存期的改善和各风险亚组的一致疗效正在推动治疗量的增加。
• 指引采纳：纳入主要临床指引正在推动全球处方量的持续成长。

6. 竞争差异化与市场趋势

• 定向ADC 机制：Poraibee 将其细胞毒性有效载荷直接递送至表达 CD79b 的 B 细胞，使其有别于传统化疗和裸抗体。
• 优化化疗平台：在第一线治疗中以长春新碱取代现有标准疗法，可以克服其疗效限制。
• 向精准医疗的转变：对标靶治疗和生物标记驱动治疗的日益重视，巩固了 Poraibi 在侵袭性淋巴瘤领域的地位。
• 真实世界数据 (RWE) 的角色日益扩大：核准后的真实世界数据增强了付款者和处方方对 Porivee 长期风险效益的信心。

波拉伊比的最新进展

在POLARIX III期临床试验中，Poraivy合併R-CHOP方案在初治瀰漫性大B细胞淋巴瘤（DLBCL）患者中展现出优于标准治疗方案R-CHOP的无恶化生存期。核准作为一线治疗方案与R-CHOP合併使用，显着巩固了Poraivy的市场地位。罗氏持续公布真实世界数据和亚组分析结果，证实Poraivy在不同患者群体中均具有持久的疗效。目前正在进行的临床计画正在探索Poraivy与其他联合治疗疗法以及在早期治疗中的应用，进一步强化其作为侵袭性B细胞淋巴瘤关键标靶治疗的地位。

《Poraivy销售预测及市场规模分析（2034）》报告全面深入地分析了Poraivy在七大主要市场（英国、四个欧盟国家（德国、法国、义大利和西班牙）、英国、瑞士和荷兰）的核准适应症（瀰漫性大B细胞淋巴瘤）以及潜在适应症（美国淋巴瘤、慢性淋巴性白血病白血病、非何杰金氏淋巴瘤）。本报告核准分析了Poraivy在2020年至2034年研究期间，在七大主要市场（美国、四个欧盟国家（德国、法国、义大利和西班牙）、英国和日本）的现有用途、预期市场准入以及在已获批和潜在适应症中的临床表现。此外，报告还详细描述了Poraivy在核准和潜在适应症的应用。这份Poraivy市场报告深入分析了Poraivy的销售预测、作用机制、剂量和给药途径，以及研发和其他开发活动，包括监管里程碑。此外，该报告还详细分析了Poraivy过去和当前的市场表现，评估了其未来市场前景（包括对七个主要国家已通过核准和潜在适应症的Poraivy市场进行预测分析），并提供了SWOT分析、分析师观点、市场竞争对手的全面概述，以及针对每种适应症的其他新兴治疗方法的概述。该报告还对Poraivy的销售额及其市场驱动因素进行了预测分析。

波利维药物概要

Polavi（Polatuzumab vedotin）是由基因泰克（罗氏）公司开发的抗体药物复合体（ADC）。它是一种人源化单株抗体，靶向B细胞特异性抗原CD79b，并透过蛋白酶可切割的连接子与微管破坏剂单甲基澳瑞他汀E（MMAE）共用价连接。 Polavi与恶性B细胞上的CD79b结合后被内化，并释放MMAE，从而抑制细胞分裂并诱导细胞凋亡。与传统化疗相比，Polavi对淋巴瘤中增殖的B细胞具有选择性细胞毒性，减少了对健康组织的影响。 2019年，Polavi获得FDA核准，用于治疗先前接受过两种或两种以上核准后復发或难治性瀰漫性大B细胞淋巴瘤（DLBCL），需与苯达莫司汀和Rituximab昔单抗联合治疗。 2023年，此药物核准昔Rituximab、Cyclophosphamide、多柔比星和泼尼松（R-CHP方案）联合治疗用于治疗未经治疗的瀰漫性大B细胞淋巴瘤（DLBCL）或高等级B细胞淋巴瘤（IPI评分≥2）。本药每21天静脉注射（1.8 mg/kg），需预先服用药物。本报告提供了Porivee的销售情况、成长抑制因素和驱动因素、上市后状况以及多项适应症的核准情况等资讯。

Poribee 市场报告的范围

本报告深入分析了以下内容：

• Porivy 的全面产品概述，包括其作用机制 (MoA)、产品说明、剂量和给药方法、已核准适应症（例如，瀰漫性大 B 细胞淋巴瘤）的研究和开发活动，以及潜在适应症（例如，滤泡性淋巴瘤、慢性淋巴性白血病、非何杰金氏淋巴瘤、里氏症）。
• 本市场报告详细介绍了 Poribee 的监管里程碑和其他发展活动。
• 该报告还重点介绍了 Porivee 在美国、欧洲和日本的成本估算和区域差异、已报告和估计的销售额，以及已通过核准和潜在适应症的研发活动。
• Poribee 的市场报告还涵盖了专利资讯、学名药上市及其对降低成本的影响。
• Poraibee 市场报告涵盖了截至 2034 年已通过核准和潜在适应症的当前和预测销售额。
• 此外，也全面介绍了每种适应症中新兴的后期治疗方法。
• Poraiby 市场报告还包含 SWOT 分析，分析师对 Poraiby 在已通过核准和潜在适应症方面的看法。

调查方法：

这份Poribee市场报告主要基于从内部资料库、一手和二手研究以及DelveInsight产业专家团队的内部分析中获得的数据和资讯。二手资讯和资料来自各种印刷和非印刷来源，例如搜寻引擎、新闻网站、全球监管机构网站、行业期刊、白皮书、杂誌、书籍、行业协会、行业入口网站以及对现有资料库的存取。

DelveInsight 的 Poribee 分析观点

• 对波拉伊比市场的详细评估

这份Poraivy市场预测报告详细评估了美国在七个主要市场（美国、四个欧盟国家（德国、法国、义大利和西班牙）、英国和日本）的市场状况，涵盖其核准的适应症－瀰漫性大B细胞淋巴瘤，以及潜在的适应症－滤泡性淋巴瘤、慢性淋巴性白血病、英国非何杰金氏淋巴瘤和里B细胞淋巴瘤。报告的这一部分提供了Poraivy截至2034年的当前销售数据和预测销售数据。

• 波莱比的临床评价

Poraiby 市场报告提供了 Poraiby已通过核准和潜在适应症的临床试验信息，包括研究干预、研究条件、实验状况、开始和完成日期。

波拉伊比的竞争格局

本报告深入分析了该领域的竞争对手和市售产品，并概述了新兴产品及其预计上市日期，这些产品将在市场上造成激烈的竞争。

Poraibee市场潜力及收入预测

• Porivee及其在主要适应症中的预期市场规模
• Poraibee 的预期销售潜力（销售尖峰时段预测）
• Porivee定价策略与报销状态

Poribee的竞争讯息

• 在研竞争药物数量（研发管线分析）
• 与现有疗法相比，Poraibee 的市场定位
• 与竞争对手相比，Poraibi 的优势和劣势

Poribee的监管和商业里程碑

• Porivee的关键监管核准和预计上市时间
• 商业合作、授权协议和併购活动

波莱比的临床分化

• 与现有药物相比，Poraiby 具有更优的疗效和安全性。
• Poraibi的独特卖点

Poribee 市场报告要点

• 未来几年，随着 Poraibee 的广泛应用、处方笺的增加以及在多种免疫适应症中的更广泛应用，其市场格局可能会发生变化，这将推动市场规模的成长。
• Poraibee相关企业致力于开发以治疗和改善疾病状态的新方法为重点的治疗方法，评估可能影响 Poraibee 优势的挑战和机会。
• 其他用于治疗瀰漫性大B细胞淋巴瘤的新兴产品，以及滤泡性淋巴瘤、慢性淋巴性白血病、非何杰金氏淋巴瘤和里氏症等潜在适应症，预计将对Porivee构成激烈的市场竞争，而近期推出的后期治疗方法预计也将对市场产生重大影响。
• 它详细描述了监管里程碑和开发活动，以了解 Porivee 在已通过核准和潜在适应症中的当前开发情况。
• 我们分析 Poraibee 的成本、定价趋势和市场定位，以支持免疫学领域的策略决策。
• 我们对 Porivee 到 2034 年的销售预测数据进行了详细分析，这将整体情况展现 Porivee 在已通过核准和潜在适应症方面的表现，从而支持您的治疗组合决策流程。

目录

第一章 报告概述

2. Poraibi 在核准的适应症（例如瀰漫性大B细胞淋巴瘤）和潜在适应症（例如滤泡性淋巴瘤、慢性淋巴性白血病、非何杰金氏淋巴瘤和里氏症候群）中的概述

• 产品详情
• Porivee临床开发
  • 波莱比临床研究
  • Poraibi 临床试验资讯
  • 安全性和有效性
• 其他发展活动
• 产品简介

第三章 波拉比的竞争格局（市售治疗方法）

第四章 竞争格局（后期新兴政策治疗方法）

第五章：政策市场评估

• Porivee已通过核准和潜在适应症的市场展望
• 对七个主要国家的分析
  • Porivee在七个主要国家已通过核准和潜在适应症的市场规模
• 各国市场
  • 美国已通过核准和潜在适应症的市场规模
  • Poliby在德国的市场规模（已通过核准和潜在适应症）
  • 在英国，Porivee 的市场规模（已通过核准和潜在适应症）

第六章 Poribee 的 SWOT 分析

第七章 分析师观点

第八章附录

第九章 DelveInsight 服务

第十章 免责声明

第十一章 关于 DelveInsight

第十二章 报告购买选项

Key Factors Driving Polivy Growth

1. Market Share Gains and New Patient Starts

• POLIVY (polatuzumab vedotin), an antibody-drug conjugate (ADC) developed by Roche, is gaining market traction in the diffuse large B-cell lymphoma (DLBCL) landscape, particularly in frontline and relapsed/refractory settings.
• New patient starts are increasing as POLIVY becomes more firmly embedded in standard treatment regimens, supported by strong survival benefits demonstrated in pivotal trials.
• Roche's targeted hematology-oncology commercial strategy, coupled with robust physician education and guideline inclusion, is accelerating adoption across academic and community oncology practices.

2. Expansion Across Key Indications

• Frontline DLBCL: POLIVY in combination with R-CHP has emerged as a key alternative to R-CHOP in previously untreated DLBCL patients, supported by superior progression-free survival outcomes.
• Relapsed/Refractory DLBCL: Continued use in combination with bendamustine and rituximab (Pola-BR) supports sustained utilization in later-line settings.
• Broader B-Cell Lymphomas: Ongoing studies are evaluating POLIVY in other aggressive and indolent B-cell non-Hodgkin lymphomas.
• Pipeline and Combination Strategies: Additional combinations with novel agents and immunotherapies may further expand POLIVY's role across treatment lines.

3. Geographic Expansion

• Global Commercial Footprint: POLIVY is approved and commercialized across major markets including the United States, Europe, and Japan.
• Emerging Markets: Expansion into emerging markets is supported by Roche's established oncology infrastructure and increasing access to advanced lymphoma therapies.
• Asia-Pacific Growth: Rising lymphoma incidence, improved diagnostic rates, and greater access to biologics are expected to support accelerated growth in Asia-Pacific regions.

4. New Indication Approvals

• Frontline DLBCL Approval: Regulatory approval of POLIVY in combination with R-CHP for untreated DLBCL significantly broadened its treatment landscape.
• Label Expansion Strength: Approvals in both frontline and relapsed/refractory settings enhance Roche's competitive positioning and diversify revenue streams.
• Regulatory Momentum: Ongoing studies may support additional label refinements or expansions into specific DLBCL subpopulations.

5. Strong DLBCL Volume Momentum

• High Unmet Need in Aggressive Lymphomas: Despite curative intent, a significant proportion of DLBCL patients relapse or fail first-line therapy, sustaining demand for improved regimens.
• Compelling Clinical Outcomes: Improved progression-free survival and consistent benefit across risk subgroups are driving strong treatment volumes.
• Guideline Inclusion: Incorporation into major clinical guidelines is reinforcing sustained prescription momentum globally.

6. Competitive Differentiation and Market Trends

• Targeted ADC Mechanism: POLIVY delivers a cytotoxic payload directly to CD79b-expressing B cells, differentiating it from conventional chemotherapy and naked antibodies.
• Chemotherapy Backbone Optimization: Replacement of vincristine in frontline regimens addresses efficacy limitations of historical standards of care.
• Shift toward Precision Oncology: Growing emphasis on targeted and biomarker-driven therapies supports POLIVY's positioning in aggressive lymphomas.
• Increasing Role of Real-World Evidence (RWE): Post-approval RWE is reinforcing payer and prescriber confidence in POLIVY's long-term benefit-risk profile.

Polivy Recent Developments

POLIVY's market position was significantly strengthened following regulatory approvals for frontline use in combination with R-CHP, based on the POLARIX Phase III trial, which demonstrated superior progression-free survival compared with standard R-CHOP in previously untreated DLBCL patients. Roche has continued to report consistent real-world and subgroup analyses supporting the durability of benefit across patient populations. Ongoing clinical programs are exploring POLIVY in additional combination regimens and earlier treatment settings, reinforcing its role as a cornerstone targeted therapy in aggressive B-cell lymphomas.

"Polivy Sales Forecast, and Market Size Analysis - 2034" report provides comprehensive insights of Polivy for approved indication like Diffuse large B cell lymphoma; as well as potential indications like Follicular lymphoma; Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma; and Richter's syndrome in the 7MM. A detailed picture of Polivy's existing usage in approved and anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 -2034 is provided in this report along with a detailed description of the Polivy for approved and potential indications. The Polivy market report provides insights about Polivy's sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current Polivy performance, future market assessments inclusive of the Polivy market forecast analysis for approved and potential indications in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of Polivy sales forecasts, along with factors driving its market.

Polivy Drug Summary

Polivy (polatuzumab vedotin) is an antibody-drug conjugate (ADC) developed by Genentech (Roche) comprising a humanized monoclonal antibody targeting CD79b-a B-cell-specific antigen covalently linked via a protease-cleavable linker to the microtubule-disrupting agent monomethyl auristatin E (MMAE). Upon binding to CD79b on malignant B cells, it internalizes, releases MMAE intracellularly, inhibits cell division, and induces apoptosis, selectively delivering cytotoxicity to proliferating B cells in lymphomas while sparing healthy tissues more than traditional chemotherapy. FDA-approved in 2019 for relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after >=2 prior therapies in combination with bendamustine and rituximab, and expanded in 2023 for previously untreated DLBCL or high-grade B-cell lymphoma (IPI >=2) with rituximab, cyclophosphamide, doxorubicin, and prednisone (R-CHP), it is administered intravenously every 21 days (1.8 mg/kg) under premedication. The report provides Polivy's sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the Polivy Market Report

The report provides insights into:

• A comprehensive product overview including the Polivy MoA, description, dosage and administration, research and development activities in approved indications like Diffuse large B cell lymphoma; as well as potential indications like Follicular lymphoma; Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma; and Richter's syndrome.
• Elaborated details on Polivy regulatory milestones and other development activities have been provided in Polivy market report.
• The report also highlights Polivy's cost estimates and regional variations, reported and estimated sales performance, research and development activities in approved and potential indications across the United States, Europe, and Japan.
• The Polivy market report also covers the patents information, generic entry and impact on cost cut.
• The Polivy market report contains current and forecasted Polivy sales for approved and potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The Polivy market report also features the SWOT analysis with analyst views for Polivy in approved and potential indications.

Methodology:

The Polivy market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

Polivy Analytical Perspective by DelveInsight

• In-depth Polivy Market Assessment

This Polivy sales market forecast report provides a detailed market assessment of Polivy for approved indication like Diffuse large B cell lymphoma; as well as potential indications like Follicular lymphoma; Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma; and Richter's syndrome in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted Polivy sales data uptil 2034.

• Polivy Clinical Assessment

The Polivy market report provides the clinical trials information of Polivy for approved and potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

Polivy Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

Polivy Market Potential & Revenue Forecast

• Projected market size for the Polivy and its key indications
• Estimated Polivy sales potential (Polivy peak sales forecasts)
• Polivy Pricing strategies and reimbursement landscape

Polivy Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• Polivy Market positioning compared to existing treatments
• Polivy Strengths & weaknesses relative to competitors

Polivy Regulatory & Commercial Milestones

• Polivy Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

Polivy Clinical Differentiation

• Polivy Efficacy & safety advantages over existing drugs
• Polivy Unique selling points

Polivy Market Report Highlights

• In the coming years, the Polivy market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The Polivy companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Polivy's dominance.
• Other emerging products for Diffuse large B cell lymphoma; as well as potential indications like Follicular lymphoma; Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma; and Richter's syndrome are expected to give tough market competition to Polivy and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Polivy in approved and potential indications.
• Analyse Polivy cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted Polivy sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of Polivy in approved and potential indications.

Key Questions:

• What is the class of therapy, route of administration and mechanism of action of Polivy? How strong is Polivy's clinical and commercial performance?
• What is Polivy's clinical trial status in each individual indications such as Diffuse large B cell lymphoma; as well as potential indications like Follicular lymphoma; Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma; and Richter's syndrome and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Polivy Manufacturers?
• What are the key designations that have been granted to Polivy for approved and potential indications? How are they going to impact Polivy's penetration in various geographies?
• What is the current and forecasted Polivy market scenario for approved and potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of Polivy in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to Polivy for approved and potential indications?
• Which are the late-stage emerging therapies under development for the treatment of approved and potential indications?
• How cost-effective is Polivy? What is the duration of therapy and what are the geographical variations in cost per patient?

Table of Contents

1. Report Introduction

2. Polivy Overview in approved indications like Diffuse large B cell lymphoma; as well as potential indications like Follicular lymphoma; Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma; and Richter's syndrome

• 2.1. Product Detail
• 2.2. Polivy Clinical Development
  • 2.2.1. Polivy Clinical studies
  • 2.2.2. Polivy Clinical trials information
  • 2.2.3. Safety and efficacy
• 2.3. Other Developmental Activities
• 2.4. Product Profile

3. Polivy Competitive Landscape (Marketed Therapies)

4. Competitive Landscape (Late-stage Emerging Polivy Therapies)

5. Polivy Market Assessment

• 5.1. Polivy Market Outlook in approved and potential indications
• 5.2. 7MM Analysis
  • 5.2.1. Polivy Market Size in the 7MM for approved and potential indications
• 5.3. Country-wise Market Analysis
  • 5.3.1. Polivy Market Size in the United States for approved and potential indications
  • 5.3.2. Polivy Market Size in Germany for approved and potential indications
  • 5.3.3. Polivy Market Size in France for approved and potential indications
  • 5.3.4. Polivy Market Size in Italy for approved and potential indications
  • 5.3.5. Polivy Market Size in Spain for approved and potential indications
  • 5.3.6. Polivy Market Size in the United Kingdom for approved and potential indications
  • 5.3.7. Polivy Market Size in Japan for approved and potential indications

6. Polivy SWOT Analysis

7. Analysts' Views

8. Appendix

• 8.1. Bibliography
• 8.2. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

12. Report Purchase Options

List of Tables

• Table 1: Polivy, Clinical Trial Description, 2023
• Table 2: Polivy, General Description
• Table 3: Competitive Landscape (Marketed Therapies)
• Table 4: Competitive Landscape (Emerging Therapies)
• Table 5: Polivy's pricing and cost Assumptions
• Table 6: Polivy's Sales Analysis in the 7MM, in USD million (2020-2034)
• Table 7: Polivy Market Size in the US, in USD million (2020-2034)
• Table 8: Polivy Market Size in Germany, in USD million (2020-2034)
• Table 9: Polivy Market Size in France, in USD million (2020-2034)
• Table 10: Polivy Market Size in Italy, in USD million (2020-2034)
• Table 11: Polivy Market Size in Spain, in USD million (2020-2034)
• Table 12: Polivy Market Size in the UK, in USD million (2020-2034)
• Table 13: Polivy Market Size in Japan, in USD million (2020-2034)

List of Figures

• Figure 1: Polivy's Sales Analysis in the 7MM, USD million (2020-2034)
• Figure 2: Polivy Market Size in the United States, USD million (2020-2034)
• Figure 3: Polivy Market Size in Germany, USD million (2020-2034)
• Figure 4: Polivy Market Size in France, USD million (2020-2034)
• Figure 5: Polivy Market Size in Italy, USD million (2020-2034)
• Figure 6: Polivy Market Size in Spain, USD million (2020-2034)
• Figure 7: Polivy Market Size in the United Kingdom, USD million (2020-2034)
• Figure 8: Polivy Market Size in Japan, USD million (2020-2034)